Evidence map›Paper›PMID 38712059›Full record

ArticlebioRxiv : the preprint server for biology2024

Cell-free assays reveal that the HIV-1 capsid protects reverse transcripts from cGAS.

Tiana M Scott, Lydia M Arnold, Jordan A Powers, Delaney A McCann, Ana B Rowe, Devin E Christensen, Miguel J Pereira, Wen Zhou, Rachel M Torrez, Janet H Iwasa and 3 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Tiana M ScottDivision of Microbiology and Immunology, Department of Pathology, University of Utah School of Medicine; Salt Lake City, UT 84112, USA.
Lydia M ArnoldDivision of Microbiology and Immunology, Department of Pathology, University of Utah School of Medicine; Salt Lake City, UT 84112, USA.
Jordan A PowersDivision of Microbiology and Immunology, Department of Pathology, University of Utah School of Medicine; Salt Lake City, UT 84112, USA.
Delaney A McCannDivision of Microbiology and Immunology, Department of Pathology, University of Utah School of Medicine; Salt Lake City, UT 84112, USA.
Ana B RoweDivision of Microbiology and Immunology, Department of Pathology, University of Utah School of Medicine; Salt Lake City, UT 84112, USA.
Devin E ChristensenDepartment of Biochemistry, University of Utah School of Medicine; Salt Lake City, UT 84112, USA.
Miguel J PereiraDepartment of Biochemistry, University of Utah School of Medicine; Salt Lake City, UT 84112, USA.
Wen ZhouDepartment of Immunology and Microbiology, School of Life Sciences, Southern University of Science and Technology; Shenzhen, Guangdong 518055, China.
Rachel M TorrezDepartment of Biochemistry, University of Utah School of Medicine; Salt Lake City, UT 84112, USA.
Janet H IwasaDepartment of Biochemistry, University of Utah School of Medicine; Salt Lake City, UT 84112, USA.
Philip J KranzuschDepartment of Microbiology, Harvard Medical School; Boston, MA 02115, USA.
Wesley I SundquistDepartment of Biochemistry, University of Utah School of Medicine; Salt Lake City, UT 84112, USA.
Jarrod S JohnsonDivision of Microbiology and Immunology, Department of Pathology, University of Utah School of Medicine; Salt Lake City, UT 84112, USA.ORCID 0000-0001-7355-5240

Funding

CHEETAH Center for the Structural Biology of HIV Infection, Restriction, and Viral DynamicsU54AI170856 · NIAID · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Michael S Kay · 2022 to 2026
$34.4M
Discovery of cGAS-like signaling enzymes in innate immunity and diseaseDP2GM146250 · NIGMS · DANA-FARBER CANCER INST · PI KRANZUSCH, PHILIP J · 2021 to 2024
$2.5M
Regulation and Manipulation of Innate Immunity During HIV InfectionR01AI181713 · NIAID · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jarrod Sean Johnson · 2024 to 2026
$2.1M
Regulation and Manipulation of Innate Immunity During HIV InfectionR56AI174930 · NIAID · UNIVERSITY OF UTAH · PI JOHNSON, JARROD SEAN · 2023 to 2023
$668k
NIAID NIH HHS R01 AI181713NIAID NIH HHS R56 AI174930NIAID NIH HHS U54 AI170856NIGMS NIH HHS DP2 GM146250
6 · The paper itself

Abstract

Retroviruses can be detected by the innate immune sensor cyclic GMP-AMP synthase (cGAS), which recognizes reverse-transcribed DNA and activates an antiviral response. However, the extent to which HIV-1 shields its genome from cGAS recognition remains unclear. To study this process in mechanistic detail, we reconstituted reverse transcription, genome release, and innate immune sensing of HIV-1 in a cell-free system. We found that wild-type HIV-1 capsids protect viral genomes from cGAS even after completing reverse transcription. Viral DNA could be "deprotected" by thermal stress, capsid mutations, or reduced concentrations of inositol hexakisphosphate (IP6) that destabilize the capsid. Strikingly, the capsid inhibitor lenacapavir also disrupted viral cores and dramatically potentiated cGAS activity, both in vitro and in cellular infections. Our results provide biochemical evidence that the HIV-1 capsid lattice conceals the genome from cGAS and that chemical or physical disruption of the viral core can expose HIV-1 DNA and activate innate immune signaling.

Indexed as

capsid inhibitioncGASDNA sensingHIVinnate immunityinterferonin vitro reverse transcriptionIRF3lenacapavirSTING

Identifiers

PMID38712059
PMCPMC11071359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.